

REMARKS

Claims 110-115, 117 and 118 are pending. Applicant thanks the Examiner for withdrawing all rejections from previous Office Actions.

I. Mogul et al. and Reaven in view of Orskov et al. and Veber et al.

Claims 110-115, 117 and 118 stand rejected under 35 USC § 103(a) as allegedly being unpatentable over Mogul et al. (J. Clinical Endocrinology, Vol. 8, No. 12, 1996, pp. 4492-4495), and Reaven (Diabetes, Vol. 37, pp. 1595-1601, Dec. 1988), in view of Orskov et al. (Metabolism, Vol. 45, No. 2, pp. 211-217, 1996) and Veber et al. (Life Sci, Vol. 34, pp. 1371-1378, 1984). However, Applicant directs the Examiner's attention to the concurrently filed Affidavit of Yarom Cohen submitted under 37 CFR . As the presently claimed subject matter of this application was invented prior to June 12, 1996, i.e., the publication date of Mogul et al., Applicant respectfully requests reconsideration of this rejection.

II. Reaven in view of Carretta et al and Verber et al.

Claims 110-115, 117 and 118 also stand rejected under 35 USC § 103(a) as being unpatentable over Reaven in view of Carretta et al. (J. Hypertension, Vol. 7, Supp. 6, pp. s196-s197, 1989).

However, claim 110 has been amended to recite "A method of treating syndrome X comprising administering to a patient exhibiting syndrome X" (emphasis added). Thus, the present claims are directed to treating syndrome X itself, not to treating a symptom of syndrome X. No new matter has been added. As the amendment is merely to clarify that which was originally intended by the claims, Applicant respectfully presents that the scope of the claims has not be changed by this amendment.

Because the cited references, either alone or in combination, do neither teach nor suggest the treat syndrome X (not just a symptom of syndrome X) by administering "a pharmaceutical composition comprising a pharmaceutically effective dosage of a compound selected from the group consisting of somatostatin or one of its analogs, diazoxide or one of its analogs, cyclothazide or one of its analogs and metformin.", Applicant respectfully requests reconsideration of the rejections presented in the most recent Office Action.

In view of the above, it is respectfully submitted that all objections and/or rejections are overcome. Thus, entry of the above amendment and passage of this application to allowance, is respectfully requested.

Respectfully submitted,

ER RL Reg. No. 45,047

TPP/EPR/mat
Attorney Docket No.: TPP 30566

Fol

Thomas P. Pavelko
Registration No. 31,689

STEVENS, DAVIS, MILLER & MOSHER, L.L.P.
1615 L Street, N.W., Suite 850
Washington, D.C. 20036
Telephone: (202) 785-0100
Facsimile: (202) 408-5200 or (202) 408-5088

Date: September 8, 2003